Dublin, June 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Uterine Cancer Forecast in 25 Major Markets 2016-2026" report to their offering.

Uterine Cancer, or Corpus Uteri, is defined as any invasive neoplasm of the uterine corpus. It most commonly occurs in the endometrium (-75% of all uterine cancers), the mucous membrane that lines the inner surface of the uterus. It is not currently known what causes uterine cancer, although it is considered to be dependent on endogenous hormonal levels for growth and in particular with exposure to excess oestrogen.

This report provides the current incident population for Uterine Cancer across 25 Major Markets (USA, France, Germany, Italy, Spain, United Kingdom, Poland, Netherlands, Austria, Sweden, Hungary, Romania, Japan, China, India, Russia, Australia, Canada, Turkey, South Korea, South Africa, Saudi Arabia, Argentina, Brazil and Mexico) split by 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight, several of the main symptoms and co-morbidities of Uterine Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Uterine Cancer include:

- Hypertension
- Diabetes
- Lynch II syndrome
- Cowden's syndrome
- Nulliparity / infertile
- Polycystic ovary syndrome

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Co-morbid Conditions Associated with the Disease

8. Methodology for Quantification of Patient Numbers

9. Top-Line Uterine Cancer Incidence

10. Stages and Histopathology of Uterine Cancer
- FIGO Staging of Uterine Cancer
- Anatomical Location of Uterine Cancer
- Major Histopathology in Endometrial Cancer
- Mutations and Frequency in Uterine Cancer

11.Abbreviations and Acronyms used in the Report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information visit http://www.researchandmarkets.com/research/22wbz7/uterine_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Women's Health

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.